Newcastle Disease Virus/HK84: Next Potential Star for Targeted Immunotherapy of Hepatocellular Carcinoma?
作者信息
Huang Weiyi, Chang Wenjun
机构信息
Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China.
Department of Navy Environmental and Occupational Health, Naval Medical University, Shanghai, China.
出版信息
J Clin Transl Hepatol. 2022 Apr 28;10(2):179-180. doi: 10.14218/JCTH.2021.00553. Epub 2022 Mar 2.
Abstract
摘要
相似文献
1
Newcastle Disease Virus/HK84: Next Potential Star for Targeted Immunotherapy of Hepatocellular Carcinoma?
J Clin Transl Hepatol. 2022 Apr 28;10(2):179-180. doi: 10.14218/JCTH.2021.00553. Epub 2022 Mar 2.
2
Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling.
J Clin Transl Hepatol. 2022 Apr 28;10(2):284-296. doi: 10.14218/JCTH.2021.00284. Epub 2021 Nov 19.
3
Therapeutic Use of Viruses: Newcastle Disease Virus HK84 Oncolytic Treatment for Hepatocellular Carcinoma.
J Clin Transl Hepatol. 2022 Oct 28;10(5):783-785. doi: 10.14218/JCTH.2022.00229. Epub 2022 Jul 29.
4
Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.
Br J Cancer. 2020 Jan;122(1):111-120. doi: 10.1038/s41416-019-0639-7. Epub 2019 Dec 10.
5
Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma.
Mol Ther Oncolytics. 2019 Mar 27;13:22-34. doi: 10.1016/j.omto.2019.03.004. eCollection 2019 Jun 28.
6
Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing.
Ann Hepatol. 2022 Mar-Apr;27(2):100677. doi: 10.1016/j.aohep.2022.100677. Epub 2022 Jan 28.
7
Is there a role for immunotherapy in hepatocellular carcinoma?
Dig Liver Dis. 2006 Apr;38(4):221-5. doi: 10.1016/j.dld.2005.12.004. Epub 2006 Feb 3.
8
Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
Immunol Lett. 2014 May-Jun;159(1-2):36-46. doi: 10.1016/j.imlet.2014.02.009. Epub 2014 Mar 7.
9
[Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].
Zhonghua Gan Zang Bing Za Zhi. 2019 Nov 20;27(11):834-837. doi: 10.3760/cma.j.issn.1007-3418.2019.11.005.
10
Steroidogenic acute regulatory (StAR)-directed immunotherapy protects against tumor growth of StAR-expressing Sp2-0 cells in a rodent adrenocortical carcinoma model.
Endocrinology. 2004 Apr;145(4):1760-6. doi: 10.1210/en.2003-0983. Epub 2004 Jan 8.
引用本文的文献
1
Tumor organoids in cancer medicine: from model systems to natural compound screening.
Pharm Biol. 2025 Dec;63(1):89-109. doi: 10.1080/13880209.2025.2458149. Epub 2025 Feb 1.
2
Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions.
Asian J Pharm Sci. 2023 Jan;18(1):100771. doi: 10.1016/j.ajps.2022.100771. Epub 2022 Dec 29.
本文引用的文献
1
Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling.
J Clin Transl Hepatol. 2022 Apr 28;10(2):284-296. doi: 10.14218/JCTH.2021.00284. Epub 2021 Nov 19.
2
Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
Int J Med Sci. 2021 Mar 30;18(11):2294-2302. doi: 10.7150/ijms.59185. eCollection 2021.
3
Hepatocellular carcinoma.
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
4
Newcastle Disease Virus at the Forefront of Cancer Immunotherapy.
Cancers (Basel). 2020 Nov 28;12(12):3552. doi: 10.3390/cancers12123552.
5
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update.
Cancers (Basel). 2020 Oct 4;12(10):2859. doi: 10.3390/cancers12102859.
6
Oncolytic viruses: how "lytic" must they be for therapeutic efficacy?
Oncoimmunology. 2019 Mar 28;8(6):e1581528. doi: 10.1080/2162402X.2019.1596006. eCollection 2019.
7
Hepatocellular Carcinoma.
N Engl J Med. 2019 Apr 11;380(15):1450-1462. doi: 10.1056/NEJMra1713263.
8
A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
Methods Mol Biol. 2015;1317:343-57. doi: 10.1007/978-1-4939-2727-2_19.
9
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
J Hepatol. 2013 Jul;59(1):81-8. doi: 10.1016/j.jhep.2013.02.022. Epub 2013 Mar 4.
10
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10.
Zotero 插件